Friday, June 12, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ischemic stroke” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 60
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 60 pipeline programs matching "ischemic stroke" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

60 results for “ischemic stroke” Back to intelligence hub

Search results

Page 1 of 3
  1. 0.9% Sodium Chloride Solution, Glenzocimab

    Pari Pharma GmbH

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial
  2. Asundexian (BAY2433334)

    Bayer HealthCare AG

    Prevention of Ischemic Stroke

    phase 3 small molecule completed

    1 trial
  3. DM199-2021-001

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  4. Direct endovascular clot retrieval

    Neuroscience Trials Australia

    Ischemic Stroke

    phase 3 other completed

    1 trial
  5. Galantamine

    Universal Integrated

    Acute Ischemic Stroke AIS

    phase 3 small molecule active

    1 trial
  6. Ginkgo Diterpene Lactone Meglumine Injection

    Universal Integrated

    Ischemic Stroke

    phase 3 small molecule active

    1 trial
  7. Ginkgo diterpene lactone meglumine injection

    Universal Integrated

    Ischemic Stroke, Acute

    phase 3 small molecule active

    1 trial
  8. IIBSP-SAV-2025-178

    The George Institute

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial
  9. Intra-arterial thrombolysis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 other active

    1 trial
  10. Intravenous thrombolysis plus tirofiban

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial
  11. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial
  12. JX10002

    Lacuna Pharma Pty Ltd

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial
  13. Low-dose rtPA

    Takeda

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial
  14. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  15. Methylprednisolone sodium succinate

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  16. PCSK9 inhibitors combined with atorvastatin/rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  17. Sovateltide, Sovateltide matching placebo

    Lacuna Pharma Pty Ltd

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial
  18. TNK-tPA

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  19. Tenecteplase

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 3 small molecule active

    1 trial
  20. The methylprednisolone sodium succinate

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  21. Tirofiban

    Universal Integrated

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial
  22. Vanish Trial

    The George Institute

    People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.

    phase 3 small molecule active

    1 trial
  23. [2025]372-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial
  24. rt-PA

    Beijing Tiantan Hospital

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.